Shanghai No.1 Pharmacy Co (600833) Fair Value & Analysis
Healthcare · CN · Market cap 2.2B CNY
Fair value as of: Aug 8, 2026
From 26 valuation models · updated 2 days ago
Share price +14.4% over the past month.
A solid business, but screening 60% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥5.50). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.
How to read this chart
60‑month range ¥7.73 – ¥16.34 · fair‑value band ¥4.02 – ¥5.50 · the ¥11.01 price screens above the ¥4.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 8, 2026.
Analysis
Shanghai No.1 Pharmacy Co (600833) currently trades at ¥11.01, while our model-based Fair Value estimate is ¥4.40, implying the stock looks roughly 60.0% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai No.1 Pharmacy Co generated revenue of 2.1B CNY at a net margin of 3.6%. Revenue declined 3.9% year over year. It earns a return on equity of 6.6%. The balance sheet holds a net cash position of 225M CNY. Fundamentals as of Aug 8, 2026
Our scenario range runs from ¥4.02 (bear case) to ¥5.50 (bull case); at ¥11.01, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -60%, 600833 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥11.85) versus Economic Profit (¥1.48). Highest evidence: Growth DCF (80).
Notify me when 600833 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai No.1 Pharmacy Co.,Ltd., together with its subsidiaries, engages in the retail and wholesale of pharmaceutical products in China. It sells food, medical equipment, health convenience products, and other commodities. The company serves medical institutions, pharmacies, commodity distribution companies, and franchise stores. Shanghai No. 1 Pharmacy Co.
Full company description
Shanghai No.1 Pharmacy Co.,Ltd., together with its subsidiaries, engages in the retail and wholesale of pharmaceutical products in China. It sells food, medical equipment, health convenience products, and other commodities. The company serves medical institutions, pharmacies, commodity distribution companies, and franchise stores. Shanghai No. 1 Pharmacy Co.,Ltd. was founded in 1992 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai No.1 Pharmacy Co reported revenue of ¥2.1B in FY2025 versus ¥1.4B in FY2021, a compound +11.1%/yr. Reported net income was ¥57.7M in FY2025, compounding +4.0%/yr from FY2021.
of which total revenue +4.6 pp · buybacks/dilution +0.1 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
600833 screens 60% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Shanghai No.1 Pharmacy Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai No.1 Pharmacy Co (600833) overvalued or undervalued?
What is the fair value of 600833?
What is the quality score of 600833?
What is the revenue of Shanghai No.1 Pharmacy Co (600833)?
What is the net profit margin of 600833?
Does Shanghai No.1 Pharmacy Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai No.1 Pharmacy Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.